Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: An open-label, dose-escalation study

Journal of Clinical Psychopharmacology

Volumn 28, Issue 4, 2008, Pages 441-446

  Findling, Robert L ^a   Kauffman, Ralph E ^b   Sallee, Floyd R ^c   Carson, William H ^d   Nyilas, Margaretta ^d   Mallikaarjun, Suresh ^d   Shoaf, Susan E ^d   Forbes, Robert A ^d   Boulton, David W ^e   Pikalov, Andrei ^d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADOLESCENT; AKATHISIA; AREA UNDER THE CURVE; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONDUCT DISORDER; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; FATIGUE; FEMALE; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HUMAN; INFLUENZA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MUSCULOSKELETAL STIFFNESS; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; PARKINSONISM; PRIORITY JOURNAL; SCHIZOPHRENIA; SCHOOL CHILD; SEDATION; SIDE EFFECT; SOMNOLENCE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; VOMITING; DOSE RESPONSE; DRUG ADMINISTRATION;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHILD; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 54449084692     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31817dd520     Document Type: Article

References (17)

1. 2 receptors. J Pharmacol Exp Ther. 2002;302:381-389.
2. Jordan S, Koprivica "V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol. 2002;441:137-140.
3. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuro- psychopharmacology. 2003;28:1400-1411.
4. Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother. 2005;6: 2091-2101.
5. McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opin Pharmacother. 2007;8:1001-1009.
6. Abilify. Bristol-Myers Squibb Company/Otsuka America Pharmaceutical Inc, Aripiprazole (Abilify) Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Co & Otsuka America Pharmaceutical, Inc; 2007.
7. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004;44:179-187.
8. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123-136.
9. Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006;189:259-266.
10. Keck PE, Calabrese JR, McQuade RD, et al. A randomized, doubleblind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. JClin Psychiatry. 2006;67:626-367.
11. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. JPsychopharmacol. 2006;20:536-546.
12. Findling R, Blumer J, Kauffman R, et al. Aripiprazole in pediatric conduct disorder: a pilot study. Eur Neuropsychopharmacol. 2003;13:S335.
13. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
14. Guy W. Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. Revised. NIMH Publication DHEW Publication No. ADM 76-338. Rockville, MD: National Institute of Mental Health; 1976.
15. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
16. Jusko W. Guidelines for collection and analysis of pharmacokinetic data. In: Evans W, Jusko W, Schentag J, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics, Inc; 1992:1- 43.
17. Mallikaarjun S, Bramer S, Kornhauser M, et al. Tolerability, safety and pharmacokinetics of aripiprazole at high doses in adults with a diagnosis of schizophrenia or schizoaffective disorder-a pilot study. Clin Pharmacol Ther. 2006;79:1-38.